Corcept Therapeutics Incorporated
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $120.5M | $127.7M | $135.6M | $66.3M | $77.6M | $76.2M | $31.3M | $41.6M |
| Accounts Receivable | $59.8M | $54.0M | $41.1M | $31.1M | $27.6M | $26.2M | $19.9M | $17.6M |
| Inventory | $12.9M | $12.4M | $7.7M | $6.1M | $5.0M | $4.9M | $5.4M | $4.7M |
| Total Current Assets | $485.5M | $471.6M | $458.6M | $499.3M | $266.5M | $478.5M | $307.4M | $236.8M |
| Property, Plant & Equipment | $1.9M | $2.7M | $195.0K | $633.0K | $1.0M | $1.7M | $1.1M | $655.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M | $571.7M | $412.3M | $311.7M |
| Liabilities | ||||||||
| Accounts Payable | $40.4M | $15.4M | $17.4M | $12.0M | $6.9M | $10.6M | $7.5M | $8.3M |
| Total Current Liabilities | $166.1M | $140.8M | $104.5M | $72.5M | $47.5M | $47.5M | $38.8M | $35.6M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M | $48.4M | $41.1M | $35.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $643.4M | $543.7M | $402.5M | $296.4M | $195.0M | $82.5M | $-23.6M | $-117.7M |
| Total Stockholders' Equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M | $523.3M | $371.2M | $275.9M |